Roivant (ROIV) Q4 2025 earnings review
GAAP Profitability is an Illusion; Batoclimab is Dead
Roivant reported 25Q4 EPS of $0.28 and a consolidated Net Income of $355.7M, completely reversing its historical trend of heavy losses. However, this profitability is an illusion driven entirely by a $770.2M one-time gain from the Moderna patent settlement. Under the hood, organic cash burn is accelerating: Adjusted Non-GAAP loss from continuing operations widened 44% YoY to $222.7M in Q4. The pipeline suffered a major blow as batoclimab was entirely discontinued following dual Phase 3 failures in Thyroid Eye Disease (TED), costing the company $39M in termination fees. The silver lining is a fortress balance sheet ($4.3B in cash) and strong Phase 2 data for next-gen FcRn IMVT-1402, which must now single-handedly carry the immunology franchise.
🐂 Bull Case
The $2.25B global settlement with Moderna permanently removes litigation overhang. Roivant recorded a $770.2M gain in 25Q4 and expects a massive $950M cash payment in July 2026, fully securing its runway to profitability without shareholder dilution.
With batoclimab dead, IMVT-1402 is now the crown jewel. It posted strong open-label data in difficult-to-treat Rheumatoid Arthritis (72.7% ACR20 at Week 16). No new safety signals were observed, validating Roivant's 'deeper is better' IgG suppression thesis.
🐻 Bear Case
Both Phase 3 TED studies missed their primary endpoints. Roivant has terminated the batoclimab program across all indications. This wipes out years of clinical investment and places intense pressure on IMVT-1402 to succeed in a highly competitive FcRn market.
Despite the headline profit, Q4 R&D expenses surged 37% YoY to $198.9M. Stripping out the settlement, the company's core operations are burning more cash than ever as it ramps up multiple registrational trials.
⚖️ Verdict: ⚪
Neutral. The influx of nearly $1 billion in non-dilutive settlement cash perfectly offsets the catastrophic clinical failure of batoclimab. The company's survival is secured, but its long-term valuation now hinges entirely on flawless commercial execution for brepocitinib and clinical success for IMVT-1402.
Key Themes
LNP Litigation Resolves in a Multi-Billion Dollar Windfall
The long-standing patent litigation against Moderna is over. Genevant (Roivant's subsidiary) and Arbutus secured a $2.25B global settlement. This is a massive driver for the company: a $950M upfront payment arrives in July 2026, with another $1.3B contingent on an appeal. Roivant booked $770.2M of this in 25Q4. This non-dilutive capital injection fundamentally alters the company's balance sheet, allowing them to fund their ambitious 11-trial clinical pipeline without tapping equity markets.
Batoclimab Program Terminated Completely
A severe negative break in trend. Topline results from two Phase 3 clinical studies for batoclimab in Thyroid Eye Disease (TED) failed to meet primary endpoints. Management didn't just halt the TED trials; they discontinued the drug across *all* indications to focus entirely on IMVT-1402. This decision resulted in an immediate $39.0M hit to 25Q4 R&D expenses for contractual termination costs. This failure puts immense pressure on IMVT-1402 to perform flawlessly.
IMVT-1402 Validates in Difficult-to-Treat RA
With batoclimab gone, IMVT-1402 is Roivant's primary growth engine. The Q4 data is encouraging: in a Phase 2 proof-of-concept trial for D2T Rheumatoid Arthritis (patients failing 2+ prior advanced therapies), IMVT-1402 delivered observed ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% at Week 16. The drug was well-tolerated with no new safety signals, confirming its potential as a best-in-class FcRn inhibitor.
Brepocitinib Pivot to Commercial Stage
Roivant is rapidly transitioning into a commercial entity. The FDA accepted the New Drug Application (NDA) for brepocitinib in Dermatomyositis (DM) with Priority Review. Commercial launch is explicitly guided for the end of September 2026. Furthermore, the drug received Breakthrough Therapy Designation for Cutaneous Sarcoidosis (CS) following strong Phase 2 data (22.3-point improvement vs 0.7 for placebo). This provides a clear path to stacked, multi-indication revenues.
Organic Cash Burn is Accelerating
Do not let the GAAP profitability fool you. Excluding the Moderna settlement, the adjusted non-GAAP loss from continuing operations widened to $222.7M in 25Q4 (from $154.4M a year ago). FY25 total non-GAAP R&D expense accelerated to $631.6M from $508.0M in FY24. As Priovant gears up for commercial launch and Immunovant pushes IMVT-1402 into larger registrational trials, base operating expenses will continue to climb.
Massive Stock-Based Compensation Dilutes Value
A specific data point contradicting the fortress balance sheet narrative is the sheer volume of stock-based compensation (SBC). In FY25, Roivant recognized $298.3M of SBC in G&A and $47.9M in R&D, totaling nearly $346M. While this preserves cash, it serves as a massive, ongoing hidden tax on shareholders that heavily suppresses true economic profitability.
Other KPIs
Stable. Roivant maintains one of the strongest balance sheets in the biotech sector. This figure does *not* include the $950M cash payment expected from Moderna in July 2026. This capital provides immense flexibility for aggressive business development (M&A) or further large-scale share repurchases, insulating the company entirely from macro capital market tightening.
Accelerating. Up 37% YoY from $145.2M. The $53.7M increase was almost entirely driven by the anti-FcRn franchise, notably including $39.0M in sunk contractual costs required to formally shut down the failed batoclimab program.
Guidance
Accelerating transition from clinical to commercial. The FDA accepted the NDA with Priority Review and a target action date in Q3 2026. This will be Roivant's first major commercial test in a market with high unmet need.
Progressing. Following a Breakthrough Therapy Designation from the FDA based on strong Phase 2 data, the pivotal program will launch in the second half of the calendar year.
Crucial catalyst path. The proof-of-concept trial for Cutaneous Lupus Erythematosus (CLE) is fully enrolled. Following batoclimab's demise, investors will be hyper-focused on these H2 2026 readouts to validate the remaining pipeline.
Stable timeline. The 135-patient trial completed enrollment within one year. This represents a major technology innovation test for their inhaled sGC activator.
Key Questions
Read-Through from Batoclimab to IMVT-1402
Batoclimab completely failed in Phase 3 TED trials. Since IMVT-1402 shares a similar mechanism of action (anti-FcRn), what specific biological or trial design factors give you confidence that 1402 will not suffer the same fate in its registrational trials?
Capital Allocation of Moderna Windfall
You are expecting a $950M cash payment in July 2026, bringing total liquidity well over $5B. In a target-rich macro environment, are you prioritizing aggressive M&A to replace batoclimab, or leaning toward further share repurchases?
Brepocitinib Commercial Readiness
With the brepocitinib DM launch guided for September 2026, how far along is the build-out of the commercial infrastructure, and what are the initial SG&A spend expectations for the launch quarters?